Algert Global LLC Has $5.41 Million Stock Holdings in Johnson & Johnson $JNJ

Key Points

• Algert Global LLC increased its stake in Johnson & Johnson by 30.2%, now holding 32,607 shares valued at approximately $5.4 million as per their latest SEC filing.
• In addition to Algert Global, several other institutional investors, including Nuveen LLC and GAMMA Investing LLC, have made significant investments in Johnson & Johnson, contributing to a 69.55% institutional ownership of the stock.
• Johnson & Johnson reported a quarterly EPS of $2.77, exceeding analysts' expectations, with a revenue increase of 5.8% year-over-year, amounting to $23.74 billion for the quarter.

Algert Global LLC lifted its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 30.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,607 shares of the company's stock after acquiring an additional 7,561 shares during the period. Algert Global LLC's holdings in Johnson & Johnson were worth $5,408,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Highline Wealth Partners LLC increased its stake in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after purchasing an additional 86 shares in the last quarter. Stone House Investment Management LLC bought a new stake in Johnson & Johnson during the 1st quarter worth approximately $47,000. von Borstel & Associates Inc. bought a new stake in Johnson & Johnson during the 1st quarter worth approximately $49,000. Harvest Fund Management Co. Ltd bought a new stake in Johnson & Johnson during the 1st quarter worth approximately $52,000. Finally, Capital A Wealth Management LLC bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $50,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on JNJ. UBS Group increased their target price on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research note on Thursday, July 17th. Royal Bank Of Canada raised their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Citigroup raised their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a research note on Thursday. Finally, Barclays raised their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $176.29.

Johnson & Johnson Stock Up 0.3%

Shares of NYSE:JNJ traded up $0.5280 during midday trading on Thursday, hitting $179.3680. The stock had a trading volume of 3,780,464 shares, compared to its average volume of 9,011,004. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $180.61. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The business's 50-day simple moving average is $162.59 and its 200-day simple moving average is $158.87. The company has a market cap of $431.98 billion, a P/E ratio of 19.19, a PEG ratio of 2.26 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same period last year, the business earned $2.82 earnings per share. The firm's revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.